IGC Pharma Inc. (IGC) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for IGC Pharma Inc. (IGC:NYSE), powered by AI.

Current Price
$0.28
P/E Ratio
-3.0
Market Cap
21M
Sector
Healthcare
What is the IGC Pharma Inc. stock price forecast?

IGC Pharma Inc. is currently trading at $0.28. View real-time AI analysis on Alpha Lenz.

What is IGC Pharma Inc. insider trading activity?

View the latest insider trading data for IGC Pharma Inc. on Alpha Lenz.

What is IGC Pharma Inc.'s P/E ratio?

IGC Pharma Inc.'s P/E ratio is -3.0.

IGC Pharma Inc.

NYSE · IGC
$0.28-0.00(-0.86%)Pre-marketNYSE regular session 09:30–16:00 ET
Ask about IGC Pharma Inc.'s future dividend policy...
Alpha Chat Insight

IGC Pharma Inc. trades at a P/E of -3.0 (undervalued) with modest ROE of -104.3%. 3Y revenue CAGR of 47.4% highlights clear growth momentum.

Ask for details

Company Overview

IGC Pharma Inc. is a pharmaceutical and biotechnology company focused on the development and commercialization of innovative therapies for the treatment of chronic pain, cancer, and other life-altering conditions. The company's primary role involves leveraging unique approaches to drug development, particularly using cannabinoids, to create novel solutions that address unmet medical needs. IGC Pharma operates within the biotech sector, which is marked by significant research and development activities and a robust pipeline of products at various stages of clinical trials. Notably, IGC Pharma's initiatives in the pharmaceutical industry aim at integrating traditional pharmaceutical methods with new advancements in cannabinoid science. This positions the company as a potential influencer in sectors such as pain management and oncology, where treatment options are continually evolving. Due to its focus on strategic research and development, IGC Pharma plays a crucial role in the broader biotechnology market, aiming to introduce cutting-edge therapies that can change the standard of care for complex medical conditions.

CEOMr. Ram Mukunda
SectorHealthcare
IndustryBiotechnology
Employees70

Company Statistics

FY 2025

Profile

$21.24MMarket Cap
$1.27MRevenue
0.00Shares Out
70Employees

Margins

48.70%Gross
-549.33%EBITDA
-585.84%Operating
-560.27%Pre-Tax
-560.27%Net

Valuation

-2.98P/E
3.36P/B
16.71EV/Sales
-3.02EV/EBITDA
-4.85P/FCF

Growth (CAGR)

47.38%Rev 3Yr
-20.77%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-76.37%ROA
-104.33%ROE
-79.85%ROIC

Financial Health

$405.00KCash & Cash Equivalents
$2.01MNet Debt
38.18%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

IGC Pharma Inc. (ticker: IGC) is a company listed on NYSE in the Healthcare sector (Biotechnology). It has approximately 70 employees. Market cap is $21M.

The current price is $0.278 with a P/E ratio of -2.98x and P/B of 3.36x.

ROE is -104.33% and operating margin is -585.84%. Annual revenue is $1M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
IGC Pharma Inc. (IGC) Stock Forecast 2026 $0.28 — Price, Financials & Analyst Targets | Alpha Lenz